Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083161 · ClinicalTrials.gov registry record · Phase 2
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Gundersen Lutheran Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00083161: Completed Phase 2 study of Lung Cancer, sponsored by Gundersen Lutheran Health System.
NCT00083161 is a Phase 2 study of Lung Cancer that has completed, run by Gundersen Lutheran Health System. The registered enrollment target is 8 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083161, a Phase 2 study of Lung Cancer, has completed, sponsored by Gundersen Lutheran Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin, etoposide, and cyclophosphamide together works in treating patients with extensive-stage small cell lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG etoposide
Study Locations (1)
Wisconsin
- Gundersen Lutheran Center for Cancer and Blood - La Crosse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2003-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00083161 record still lists
NCT00083161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT00083161 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00083161 about?
NCT00083161 is a clinical study titled "Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giv...
What is the current status of trial NCT00083161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2003-06. Estimated completion is 2010-05.
What conditions does trial NCT00083161 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00083161?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG).
Who is sponsoring clinical trial NCT00083161?
This trial is sponsored by Gundersen Lutheran Health System, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083161 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00083161's enrollment target sits among peer trials
8 399th of 409 higher than 9 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia